BMS, Compugen to evaluate Opdivo-COM701 combo in advanced solid tumors
While Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, COM701 is an investigational anti-PVRIG antibody. Apart from the clinical trial collaboration, Bristol-Myers Squibb has agreed to make